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Abstract 
This paper is intended to comprehend the dynamics interaction within Indonesia healthcare competition that might lead to 
the unhealthy conducts resulting in harming society and business harmony. It was analyzed by describing market structure 
using Porter’s five forces competition based on descriptive analysis approach to determine whether the structure was 
conducive for unhealthy competition or not. The intensity of competition within industry is low as a result of the weakness 
of consumer bargaining power, the strong bargaining power of providers, the malfunction of substitution availability, and 
the barriers of market entry. The pertinent findings include the existing of consumer service and price discrimination due to 
asymmetry information, the tendency of providers to integrate vertically and horizontally, as well as the dependency of 
society to public insurance. The result would be relevant to develop Indonesia healthcare policy to minimize unhealthy 
competition and to maximize the benefit for society. The findings also imply the necessity of further studies to reevaluate 
and realign the business practices in Indonesia health care industry. 
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1. Introduction 
There has been a fundamental difference between the Law of Antimonopoly and Unhealthy Competition and the practices 
of business competition in healthcare industry in Indonesia. Indeed, this issue has also been prolonged concerned by many 
researchers regulators, and medical community, among others are collusion among healthcare providers, the impact of 
competition to healthcare quality, and market domination of healthcare providers (Briefing Paper CUTS, 2008; Barlo M., 
2006; Pauly M.V., 2004; and Bates L.J. and Santere R.E., 2008).   
Similar tones are also found in Indonesia including a substantial amount of people's complaints regarding the consumer 
discrimination, low community accessibility to the quality of health services, and market domination by only a few 
pharmaceutical companies (Sparrow et al, 2010; Thabrany et al, 2003; Tempo, April 8
th
 2001). Another fact indicating the 
practices of unhealthy business competition in the health care industry was the finding of many transfer notes from one of 
the largest pharmaceutical company in Indonesia into hundred accounts of physicians, pharmacists, and hospital 
administrators scattered in various cities in Indonesia (Tempo, April 8
th
 2001).    
Since the health development in Indonesia is one of the most important pillars of the national development achievement, the 
government has issued various policies to stimulate the growth of the industries as an important player in supporting the 
achievement of health development goal. At one hand such growth is expected to increase the affordability of quality, 
equity, and accessibility of health services for societies. On the other hand, such growth is vulnerable to the proliferation of 
unhealthy competition. Therefore, it is very important to prevent the competition from unhealthy business practices to 
assure the achievement of the national health development goal as well as to maintain the business harmony. 
2. Background 
Market-oriented reforms in the health sector continue to dominate health policy agendas in many developing countries 
including Indonesia despite growing evidence of their negative impacts. Health care competition has taken various forms 
where different players such as hospitals, insurances and physicians struggle to reach a niche market position (Griffin, 1992; 
Wagstaff, 2007).  
The concept of industrial organization developed by Mason (1939, 1949) and Bain (1959) in Carlton and Perloff (1994) has 
been well proven in analyzing   the strategic choices of firms within industries including market structure and competition in 
the healthcare sector. This concept has also given a great contribution in breaking down many different perspectives and 
strategies, which leads to contribute to policy development field in a quite different perspective from its pure concept 
(Mason, 1939, 1949; Bain, 1959 in Carlton and Perloff, 1994).   
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Based on that concept, the structure of an industry will influence the behavior or conduct of firms, and subsequently firm’s 
conduct will determine the performance of the industry (Bain, 1968; Mason, 1953). In addition, Porter (1980) introduced the 
Five Forces of Competition model as a basis for a competition analysis consisting of the bargaining power of supplier, the 
bargaining power of consumer, the barrier of entry, the availability of substitutes, and the intensity of rivalry within 
industry.   
Unfortunately, perfectly competitive markets exist only in economic theory.  In reality, industries and markets have varying 
constraints on competition. Evans, R.G. (1984) stated that the healthcare industry has often been characterized as unique in 
its many significant barriers to free market competition. Most of the inhibition from healthcare market controls on price and 
quality result coming from various factors as follows: (1) The Asymmetry of Information between Providers and 
Consumers/Patients. Most consumers have limited information about their illness and their treatment options. Consumers 
with chronic illnesses are supposed to have more opportunity and incentive to gather such information, but there is still a 
fundamental informational asymmetry between providers and patients; (2) Consumer Uncertainty about Reliability of 
Health Care Information. Uncertainty increases transaction costs, fraud, and deception dramatically; (3) The nature of health 
creates an unpredictable, urgent, and infinite level of demand; (4) The intensive involvement of insurance, private and 
governmental, as an intermediary in the purchase of healthcare interferes with consumer motivations and consequently 
their choice of providers and services; and (5) The difficulties in measuring healthcare quality and beneficial outcomes 
(both of quantifying and qualifying) and the lack of information on the relative costs of healthcare providers and services 
also inhibits consumer selection (Evans, R.G.,1984; Cimasi, R.J., 2000; and Gaynor, M. and Vogt, W. B., 2000). 
Gaynor, M. & Vogt, W. B. (2000) and Harbage & Davenport, (2009) also added the unique characteristics of health care 
industry i.e., uncertainty, unpredictable, complex, asymmetry information between consumers and health care providers, 
customization, consumer ignorance, non profit motive, health as human right, and externality. 
The important issues related to health care competition are clinical integration and collusion in health services. Gilfillan, 
M.D., J. Richard, et. al, (2010) stated that despite a clinical integration provides the ability to improve health care quality 
and  more effective business strategy, but may also lead to higher costs through increased market leverage with payers. The 
cost of integration, which include practice acquisition, administration, information technology, operating infrastructure 
development, and ongoing practice support, can also be a barrier (Hayford, Tamara B., 2008). 
In a separate article, Gupta S, Davoodi HR, Tiongson ER, (2002) and Kassirer J., (2006), stated that collusion in health care 
is a universal phenomenon noticed amongst both Western and non-Western societies that subsequently may lead to harm the 
patients. In a broad term, collusion is defined as a secret agreement or cooperation between two or more people who are 
trying to deceive. In healthcare, collusion implies any information (about the diagnosis, prognosis, and medical details about 
the person who is ill) being withheld or not shared among individuals involved. Collusion also means that relevant and 
complete medical information is selectively or not disclosed at all to patients and/or relatives. The ultimate burden of such 
collusion falls on the consumer – inappropriate, excessive or costly medication; unnecessary and expensive diagnostic tests; 
prolonged and expensive hospitalisation etc (Giedion U, Morales LG, Acosta OL., 2001). 
In health care markets, the antitrust laws have played an integral role; among others are protecting consumers  from higher 
prices resulting from efforts to reduce or eliminate price competition, preventing providers from boycotting innovative 
health care delivery systems, preventing consumers from providers who form joint agreement to increase their fees above 
competitive levels and pass those unjustified increases benefits to consumers, and preventing from anticompetitive mergers 
that would result in diminished services, decreased quality and increased prices (Baker, J.B., 1988; Blackstone, E.A. and 
Fuhr J.P., 1984).  
In the case of health care markets, however, the antitrust laws are enforced not only to take into account on the indications 
of possible competitive harm, but also the potential for procompetitive increases in efficiency, lowered administrative and 
other costs, improvements in quality, enhanced innovation, and other factors that are important to the cost-effective delivery 
of quality health care services. Bingaman A.K, (1994) found that many joint activities and types of procompetitive activity 
could lead to lower costs and improved quality in the health care industry without raising any antitrust issues. 
In parallel with the development of economy, the government of the Republic of Indonesia has introduced the antitrust law 
in the year of 1999, entitled “Law of Antimonopoly and Unhealthy Competition”. Meanwhile at the beginning of the year of 
2010, The Ministry of Health (MoH) of the Republic of Indonesia launched a National Health Strategic Plan for 2010–2014. 
The plan outlines the importance of increasing access to and quality healthcare services for middle-income and low-income 
families, at an affordable price. In recent years, the cost, quality, and accessibility of Indonesian health care have become 
major legislative and policy issues. Therefore, it is necessary to analyze the profile of healthcare market in Indonesia to 
assure that the national health strategic goals can be achieved effectively.  
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3. Methods 
This study was carried out using a qualitative descriptive approach. Various data were obtained from individual and group 
interviews through purposive selection. The units of analysis in this study were the dynamics of interactions among hospital, 
patients, pharmaceutical companies, health insurances, and physicians.  
The study was conducted in three major cities in Indonesia i.e. Jakarta, Makassar, Surabaya. Selection of the three cities 
were selected purposively because these three cities reflect the portrait of health services in Indonesia due to the 
heterogeneity of economic, social, political, cultural, or religious.  
The study was conducted at two private hospitals and two government hospitals in each city. Respondents in this study were 
(1) patients, (2) top hospital management, (3) middle and lower hospital management related to the procurement of drugs, 
physician recruitment, legal cooperation, administration, and finance, (4) physicians, (5) pharmacy staff, (6)  big 
pharmaceutical companies staff, and 7) health insurance staff.  
The methods of data collection were as follows: (1) in depth interview using laddering technique, (2) focus group 
discussion, (3) survey, (4) participatory observation, (5) mystery shoppers, and (6) document review.  
4. Results and Discussions 
The competition profile of Indonesia healthcare industry is described in the following sections: 
4.1  Bargaining power of the consumers. 
Bargaining power of consumer is described by the following variables:  concentration ratio of payment type, tariff pattern, 
utilization value of health services, information exposure, choice of medical diagnostic services, the availability of 
substitutes, health services differentiation, drug price comparison, and the cost structure.  
The concentration ratio of payment type showed the increasing number of public insurance patients as well as declining 
number of out of pocket patients from year to year. Most of the patients are concentrated in different group health insurance 
whether public or private insurance, but most of them are covered by public insurance.  
For the tariff pattern, there are found that for the same treatment has different tariff for each type of treatment class, types of 
payment, and type of installations even in the same hospital. So, with the same input, the patients have to pay different 
tariff. The higher type of class treatment the more expensive the tariff of treatment, physician’s visit, and medical diagnostic 
examination. Similarly, each insurance company assigned a different tariff. In some hospitals, even the tariff for public 
insurance patients such as JAMKESMAS (society health insurance) is much more expensive than the out of pocket patients. 
Similar pattern also found at different installations in the same hospital. For example different tariff are applied among 
Emergency Unit, inpatient, and outpatient tariff for similar services and actions. Some of hospitals observed even set 
different prices for the same drug at different installation. There are also different tariff between corporate patients and 
insurance patients, due to tied in sales occurred. Such differences obviously indicate the presence of price discrimination. 
Attention has to be paid since the largest utilization value come from insurance patients including public insurances, private 
insurances, and corporate patients. This indicates the big magnitude of the bargaining power of insurance especially in 
determining the type and the cost of health services as well as the way it is delivered. Therefore, moral integrity of the 
institution is very important to protect the communities from disadvantages in terms of cost and receiving the most 
appropriate and valuable services according to their needs.  
Due to information exposure, most patients did not receive complete information regarding the estimation of overall cost 
and treatment length, the choices of alternative treatments and its possible consequences. The lack of knowledge make 
patients tend to just follow what the hospital or physician recommended regardless of the services or drugs are the most 
suitable or valuable for them or not. Besides ignorance, the patient also has the feeling of obligation to buy medicine and to 
do medical diagnostic examination as appointed by hospital or physician. 
There are also horizontal and vertical integration between health care providers which weaken the bargaining power of 
consumers, which will described at the following sessions.  
4.2. The availability of health care substitutions  
Although the substitutions of health services are widely available, but the market mechanism does not apply since the price 
is not determined by supply and demand due to asymmetry information.  As a matter of fact the drug’s price remains high 
even though there is sufficient drug’s brand available in the market as well as many suppliers. Currently, there are more 
than 200 pharmaceutical companies in the industry but the real market structure is still far from perfect competition as 
reflected by only about 7 pharmaceutical companies dominated the market. Indonesia Health Statistics  shows that more 
than 50% of drug trades occur in the hospital, while the price is fully determined by hospital or pharmacies.  
European Journal of Business and Management                                                                                                                          www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol 4, No.11, 2012 
 
97 
Drug’s brand is fully determined by the physician unless there are patients who have medical knowledge that ask to 
substitute the brand, then their request will be considered. Some drug’s brands that are written by physician sold only at 
certain pharmacies limiting patient’s choice to seek other preferable pharmacies. Some of the physicians already have 
integration with the pharmacy and medical diagnostic services for referral.  
At some hospitals, patients also steer to reimburse prescription in hospital pharmacies as well as doing medical diagnostic 
examination in the same hospital. Even some hospitals do not allow patients to buy drugs outside of the hospital with the 
argument of assuring drug authenticity.  
Moreover, public insurance patient could only obtain particular medicines that have been specified in the agreement 
between the hospital and the public insurance. But this is not in the case of the patients who can afford the more expensive 
services. 
The consumer ignorance leads to their inability to know the availability of such substitution. This condition is worsened by 
the conduct of hospital or physician who tends to steer patients to utilize certain medical diagnostic services, choose 
particular brand of drug, or buying drugs in certain appointed pharmacies. Actually there is big price dispersion in health 
services substitution as well as drugs.  
The limitation is much bigger for public insurance patients. The patients who covered by public insurance are regulated in a 
hierarchical referral system. Firstly, they have to examine their health at primary care services in their domiciled. If the 
patients require more intensive care and more complete facilities that cannot be provided, then they will be referred to a 
referral hospital in the same administrative region. This process is done in stages until the center of referral hospital. In 
practice however, the referral hospital is often farther than the other referral hospitals located outside the administrative 
territory adjacent. As a result, sometimes patients do not received prompt services. This is due to the consequence of the 
district autonomy policy.  
The ceiling of health insurance costs vary between different hospitals and different districts or regions. Consequently, it has 
caused the limitation to selecting the preferred medical diagnostic services such as radiology and laboratory in fulfilling 
their healthcare needs. 
The different type of insurance also applies different tariff for the same services in the same hospital. For example the tariff 
for class III determined by local government is 20,000 in IDR whereas the tariff prescribed class III determined by ASKES 
(Public Health Insurance) is 80.000 in IDR including routine laboratory examination. The difference in that tariff can still be 
claimed by the hospital even though laboratory tests are not carried out. Attention should be given to assure that patients 
will obtain maximum health services.  
4.3 Bargaining power of providers of health care services 
There are some agreements among public hospital in the same region in determining the same tariff, which may use 
different inputs. These agreements are strengthened by the regional or district regulation. This may potentially lead to the 
discrimination of services since the patients must pay the same tariffs for different health care facilities and equipment of 
different types of hospitals.  
Some hospitals determine a multi pricing tariff. There have been different tariff for the same input in the different class of 
treatments, in the different installations, and in the different payment type within the same hospital. The tariff differences 
include medical treatments, physician visits, medical diagnostic services, and drug prices. These clearly indicate the 
occurrence of price discrimination. Some hospitals integrate the services of both outpatient and inpatient to a certain 
pharmaceutical and medical diagnostic services. Although such integration may eventually increase the efficiency and 
comfort of patients, but attention must be paid when the integration is intentionally directed to patients to utilize the services 
they do not need or burdened higher price. Implicitly, it seems that there has been a tariff agreement between the specialists. 
This is indicated by the prevalence rates of certain medical specialists in certain areas. 
4.4. Barriers to entering the health care industry for new entrants 
The new entrants are relatively difficult to enter the market since the alliance between incumbent and other business actors 
in the health care industry has been well established. Such difficulties are a form unhealthy competition. 
 Based on the interview, unhealthy competition has been found in various forms among pharmaceutical companies by 
giving souvenirs, conducting or sponsoring a symposium arranged by hospitals or physicians, conducting direct approach to 
the physicians by offering discounts or assistance for continuing medical education, providing a free seminar invitations and 
transportation costs, prioritizing many physicians who recommend products. These practices are vulnerable to actions that 
violate the Indonesia Anti Monopoly and Unhealthy Competition Law. 
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In the Article 13 paragraph (2) Law of Consumer Protection stated that the business actors shall be prohibited from offering, 
promoting, or advertises drugs, traditional medicines, food supplements, medical devices, and health care services by 
promising rewards in the form of goods or other services. Prohibition as mentioned above is certainly intended to protect 
consumers from selecting the goods or services that are not for the sake of the benefit of the goods or services, but because 
of the influence of reward. Perhaps the question arises, whether the consumer can be equated with the physicians, since the 
law governing prohibition is the Consumer Protection Act.  
In addition, The Indonesia Anti Monopoly and Unhealthy Competition Law stated that the action taken by business actors to 
provide discounted prices or give certain gifts to other business actors is prohibited since it may also block the new entrants. 
In article 13 of the Law also stated that business actors shall be prohibited from engaging in one or more activities, either 
alone or together with other business actors, which may result in monopolistic practices and or unfair business competition. 
Therefore, giving particular gifts to offer products that are related to health as prohibited by the Consumer Protection Act 
should be avoided since it has a potential to the occurrence of violations of the Act and the Consumer Protection Act and the 
Anti Monopoly and Unhealthy Competition Law.  
Basically, healthcare providers can establish cooperation each others as long as such cooperation follow the Law of 
Antimonopoly and Unhealthy Competition.  
4.5.    The intensity of competition within health care industry 
The intensity of competition within health care industry is relatively low. This is indicated by unknown differentiations 
among different drugs, different specialists, different equipment, and different facilities despite the fact the price dispersion 
is high. Sometimes the drug’s price and the tariff of specialists, hospital facilities and equipment, and medical diagnostic 
examination are different even though the input are the same or vice versa due to dominant power of healthcare providers in 
the market.  
There are also large differences in drug prices among health care providers since hospitals fully determine the drugs price. 
In one of participatory observations, the drug was sold nearly 1000% over the HET (Highest Price Level). The prices of 
drugs may also be different for different payment types and different installations in the hospital. Meanwhile, once patients 
being treated in a certain hospital, they have no choice to find other affordable pharmacies. The patients treated at VIP class 
generally are given branded medicine which is more expensive than the patients of class III who usually are given generic 
drugs. Such phenomenon indicates the weak of consumer bargaining power.     
As a result, the cost structure also varies in tariffs of health services and drug’s prices for different class of treatment, 
different payment types and different installations. This indicates the occurrence of price discrimination that may need 
further considerations to protect the rights of the consumers. 
5. Conclusions and Recommendations 
5.1 Conclusions 
5.1.1. Bargaining power of consumers in health care industry is weak; on the other hand the bargaining of healthcare 
providers is strong, due to several factors as follows; 
a. The asymmetry of information and consumer ignorance causes inability of consumers to determine the products 
and services which are mostly suitable and valuable for them. 
b. In most cases businesses in the healthcare industry tend to integrate vertically and horizontally. 
c. Recently market structure tends to form a powerful force to public insurance. Policies and mechanisms in public 
insurance is relatively open the possibility of discrimination in price and service. On the other hand, the 
dependency level of societies and hospitals to public insurance is very high. 
d. The availability of health service provider is smaller than the demand for health services. 
5.1.2. The availability of health care substitution is relatively high but restricted to be utilized due to asymmetry 
information.  
5.1.3. There are barriers to enter the health care industry in Indonesia due to the vertical and horizontal integration as well as 
the resistance of the incumbent. Such barriers are also caused by the existing big pharmaceutical and health equipment 
companies that have been dominating the market.  
5.1.5. The intensity of the health care industry competition is relatively low although the number of hospitals, insurance 
companies, and pharmaceutical companies are quite large. Low competition is primarily because of asymmetry of 
information, vertical and horizontal integration between providers who have dominant power.  
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5.2.  Recommendations 
5.2.1. Required regulation and supervision regarding the vertical and horizontal integration in order to avoid price and 
service discrimination.  
5.2.2. Required regulation and supervision to govern the referral system to assure societies could receive prompt service. 
6. Implications and Limitations 
Some findings indicated a conduct against The Law of Anti Monopoly and Unhealthy Competition in Indonesia. 
However, health care industry has unique characteristics; therefore it might be inappropriate to apply the law in such 
industry. This phenomenon needs further studies regarding antitrust and healthy competition in health care industry. 
The research has some limitations; among others are the secondary data for integration between pharmaceutical 
companies, hospitals, health insurances, medical diagnostic services, and physician. The research was also conducted 
among a relatively small sample, and there is a lack of previous literature evidence to make significant comparisons.  
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